Medtronic said Monday the U.S. Food and Drug Administration has approved an adaptive brain-stimulation device as a treatment ...
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...
The "U.S. Deep Brain Stimulation In Parkinson's Disease Market Size, Share & Trends Analysis Report By Product ...
The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.
For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...
T here is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain ...
The BrainSense Adaptive technology is an enhancement to Medtronic’s Percept DBS neurostimulators. The advancement personalizes therapy based on a patient’s brain activity in real-time. Therapy ...
The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized ...
Recent developments in the health sector include Pfizer appointing Patrizia Cavazzoni as Chief Medical Officer and Amgen ...
The FDA has approved adaptive deep brain stimulation (aDBS), a breakthrough therapy that adjusts in real time to Parkinson’s disease symptoms.